Allergan, Valeant agree on meeting date. Now, the fight for shareholder votes

Switzerland wants to slash drug prices? Not so fast, say Novartis and Roche

Pfizer, Ranbaxy prevail in antitrust fight over Lipitor generics

Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting blockbuster Lipitor.

Salix hands off Relistor, other drugs to Lupin in Canada

Salix Pharmaceuticals, which has its hands full with a tax inversion merger and the integration of Santarus, will hand off Canadian sales of some of its drugs to India's Lupin. The package includes Salix's opioid constipation drug Relistor, a drug which has fallen far short of its initial potential.

Mylan, Ranbaxy, others to bring cheap Sovaldi to 91 markets

Cheap Sovaldi is on the way, and it could very well be coming to an emerging market near you. Gilead has ironed out a licensing deal for the hep C wonder with 7 companies–including Mylan and Ranbaxy–and they'll bring low-cost copies to 91 developing countries.

Lilly says with new data, it will seek another approval for Cyramza next year

Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.

Lilly says with new data, it will seek second approval for Cyramza next year

Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.

As America’s diabetes problem grows, so do prices on Lilly’s Humulin

Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.

Amarin loses a second FDA appeal over omega-3 pill Vascepa

Amarin and its omega-3 pill have struck out with the FDA again. The Irish company said today that the agency has again turned down its appeal to reconsider its clinical data it hoped would help it win a label extension for Vascepa, dealing a new blow to its efforts and its financial well being. This FDA first rejected Amarin's request in January.

Novo and Orexigen obesity drugs are coming, but will consumers embrace them?

On Thursday, the FDA got advice from an advisory panel that it should approve Novo Nordisk's Saxenda for obesity. Its approval would add to a struggling category a player whose expertise is with doctors treating diabetes, the physicians more likely to prescribe the drugs.

View sitemap

ob_end_flush();